Frederick L. Locke, MD, discussed cema-cel's safety, efficacy, and potential for treating large B-cell lymphoma in earlier ...

Treatment of B-cell Acute Lymphoblastic Leukaemia has improved thanks to CAR-T therapies, but relapse is still very common.

B-cell lymphoma is currently treated with chemotherapy, radiation, immunotherapy, and targeted therapy. Most current research focuses on the last two types. Immunotherapy fires up the immune ...

B-cell acute lymphoblastic leukemia (B-ALL) is a life-threatening and highly aggressive form of blood cancer. It is the most ...

Treatment of B-cell Acute Lymphoblastic Leukaemia has been greatly improved by CAR-T therapies, but relapse is still very common. An international team has now found in animal models a new approach ...

In just over a year since its US Food and Drug Administration (FDA) approval, pirtobrutinib (Jayprica) has become a standard ...

An indigenously developed CAR T-cell gene therapy has achieved a 73% response rate for certain blood cancers in India. The ...

Oncologists are increasingly favoring CAR T-cell therapy’s early-line use in relapsed/refractory multiple myeloma despite ...

India's gene therapy for blood cancers shows 73% response rate, offering hope and cost-effective treatment for patients.

Malabar Cancer Centre (MCC) in Kannur successfully implements CAR T-cell therapy, a groundbreaking treatment for blood cancer ...